• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Marijn Dekkers, An apple a day is no longer enough, GCF2012 presentation
 

Marijn Dekkers, An apple a day is no longer enough, GCF2012 presentation

on

  • 1,065 views

Marijn Dekkers, GCF2012 presentation, An apple a day is no longer enough

Marijn Dekkers, GCF2012 presentation, An apple a day is no longer enough

Statistics

Views

Total Views
1,065
Views on SlideShare
1,065
Embed Views
0

Actions

Likes
0
Downloads
8
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Marijn Dekkers, An apple a day is no longer enough, GCF2012 presentation Marijn Dekkers, An apple a day is no longer enough, GCF2012 presentation Presentation Transcript

    • GCF 2012 “ The Entrepreneurship Imperative” 21-24 January 2012 Dr. Marijn Dekkers Chairman of the Board of Management of Bayer AG An Apple A Day Is No Longer Enough?
    • Aging Population – In This Respect We Are Getting Healthier Source: OECD Increase of global average life expectancy Percent of global population aged 65 years+ Source: OECD
    • We Are Getting Healthier – Pharma Industry Contributions Source: IMS World Review, 1980-2010 *non-currency-adj. Pharma Industry with steady sales growth CAGR + 9 % Number of FDA-approved new pharmaceutical drugs Pharma Industry R&D–output on high level Adapted from: Munos, Lessons from 60 years of pharmaceutical innovation, Nature Reviews, December 2009. Global audited pharmaceutical drug sales* US$ bn *non-currency-adjusted
    • Source: The Global Burden Of Chronic Diseases, JAMA 2004 – Source derived from data in World Health Report 2003 *Chronic Obstructive Pulmonary Disease **Non-Communicable Diseases 0 10 20 30 40 50 60 1990 2002 2020 Cardiovascular Diseases Other NCD** COPD*, Asthma Diabetes Mellitus Chronic Illness – Global mortality vs. growth of world population Cancer At The Same Time Increase Of NCDs – Change Of Lifestyle 0 50 100 150 200 250 1963 1973 1983 1993 2003 Mio. t developing countries industrialized countries Source: faostat.fao.org Increase of global meat production NCDs +2% CAGR World population +1% CAGR No. of deaths mio.
    • Parallel Effect: Improved Diagnostics – More NCDs Diagnosed Computed Tomography exams USA, total Magnetic Resonance Imaging exams USA, total Number in Mio Source: OECD
    • Pharma Innovation At Bayer What it does Status Cardiology Xarelto ® Prevents Thrombosis
      • Approved in U.S. EU and Japan for prevention of stroke
      Riociguat Lowers Blood pressure in the Lung
      • Results of clinical phase III study expected December 2012
      Oncology Regorafenib Inhibits Tumor Growth
      • Phase III study on colorectal cancer successful
      • Application for approval planned in Q2 2012
      Alpharadin Targeted treatment of bone metastases in prostate cancer
      • Phase III study successful
      • Application for approval planned in Q2 2012
      Ophthal- mology VEGF Trap-Eye Prevents irregular blood vessels in the back of the eye
      • Approved in the U.S. for wet AMD
      • Approval in EU expected June 2012
    • Continuous Effort Required – Significant Medical Need Re. NCDs Will Persist Top 10 killers worldwide Source: McKinsey
      • Ischaemic heart disease
      • Cerebrovascular disease
      • Lower respiratory infections
      • Chronic obstructive pulmonary disease
      • HIV/AIDS
      • Diarrhoeal diseases
      • Tuberculosis
      • Respiratory cancers
      • Childhood-cluster diseases
      • Hypertensive heart disease
      • Ischaemic heart disease
      • Cerebrovascular disease
      • HIV/AIDS
      • Chronic obstructive pulmonary disease
      • Lower respiratory infections
      • Respiratory cancers
      • Stomach cancer
      • Hypertensive heart disease
      • Nephritis and nephrosis
      • Liver cancer
      10. 10. 2030 2005
    • Rising R&D Expenditures – Adequate Rewards? Source: FDA, PhRMA, Bank of Amerika Merrill-Lynch Global Research Worldwide R&D spending (indexed, 1996 = 100) FDA approvals new pharmaceutical drugs (indexed, 1996=100)
    • Dr. Marijn Dekkers Chairman of the Board of Management of Bayer AG